The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 12, 2010, Pages 1178-1187

  Ferrari, Paolo ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase; Aldosterone; Blood pressure; Cortisol; Distal renal tubule; Glucocorticoid; Mineralocorticoid; Sodium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CORTICOSTEROID; HYDROCORTISONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; DNA FLANKING REGION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ESSENTIAL HYPERTENSION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLYCYRRHIZA; HALF LIFE TIME; HORMONE METABOLISM; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOKALEMIA; KIDNEY COLLECTING TUBULE; KIDNEY FAILURE; MICROSATELLITE MARKER; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; TISSUE DISTRIBUTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; COLON; CORTICOSTERONE; HUMANS; HYDROCORTISONE; HYPERTENSION; KIDNEY; MICROSATELLITE REPEATS; RECEPTORS, MINERALOCORTICOID; RODENTIA; SODIUM;

GLYCYRRHIZA; RODENTIA;

EID: 78049291946     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.10.017     Document Type: Review

References (119)

1. Werder E.A., Zachmann M., Vollmin J.A., Veyrat R., Prader A. Unusual steroid excretion in a child with low renin hypertension. Res. Steroids 1974, 6:385-389.
2. McLachlan M.S., Beales J.S. Retroperitoneal pneumography in the investigation of adrenal disease. Clin. Radiol. 1971, 22:188-197.
3. Atanasov A.G., Ignatova I.D., Nashev L.G., Dick B., Ferrari P., Frey F.J., Odermatt A. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J. Am. Soc. Nephrol. 2007, 18:1262-1270.
4. New M.I., Levine L.S., Biglieri E.G., Pareira J., Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J. Clin. Endocrinol. Metab. 1977, 44:924-933.
5. Ulick S., Levine L.S., Gunczler P., Zanconato G., Ramirez L.C., Rauh W., Rosler A., Bradlow H.L., New M.I. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J. Clin. Endocrinol. Metab. 1979, 49:757-764.
6. Funder J.W. Why are mineralocorticoid receptors so nonselective?. Curr. Hypertens. Rep. 2007, 9:112-116.
7. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
8. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
9. Krozowski Z.S., Funder J.W. Renal mineralocorticoid receptors and hippocampal corticosterone- binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. U S A 1983, 80:6056-6060.
10. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., de Kloet E.R., Monder C. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989.
11. Funder J.W. RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 2005, 93:121-125.
12. Agarwal A.K., Monder C., Eckstein B., White P.C. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J. Biol. Chem. 1989, 264:18939-18943.
13. Tannin G.M., Agarwal A.K., Monder C., New M.I., White P.C. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J. Biol. Chem. 1991, 266:16653-16658.
14. Walker B.R., Campbell J.C., Williams B.C., Edwards C.R. Tissue-specific distribution of the NAD(+)-dependent isoform of 11β-hydroxysteroid dehydrogenase. Endocrinology 1992, 131:970-972.
15. Albiston A.L., Obeyesekere V.R., Smith R.E., Krozowski Z.S. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell Endocrinol. 1994, 105:R11-R17.
16. Agarwal A.K., Mune T., Monder C., White P.C. Cloning of cDNA encoding an NAD(+)-dependent isoform of 11β-hydroxysteroid dehydrogenase in sheep kidney. Endocr. Res. 1995, 21:389-397.
17. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R., Seckl J.R., Mullins J.J. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14924-14929.
18. Holmes M.C., Kotelevtsev Y., Mullins J.J., Seckl J.R. Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes. Mol. Cell Endocrinol. 2001, 171:15-20.
19. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., Seckl J.R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 2001, 276:41293-41300.
20. Ferrari P., Smith R.E., Funder J.W., Krozowski Z.S. Substrate and inhibitor specificity of the cloned human 11β-hydroxysteroid dehydrogenase type 2 isoform. Am. J. Physiol. 1996, 270:E900-904.
21. Li K.X., Obeyesekere V.R., Krozowski Z.S., Ferrari P. Oxoreductase and dehydrogenase activities of the human and rat 11β-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology 1997, 138:2948-2952.
22. Naray-Fejes-Toth A., Watlington C.O., Fejes-Toth G. 11β-hydroxysteroid dehydrogenase activity in the renal target cells of aldosterone. Endocrinology 1991, 129:17-21.
23. Krozowski Z., MaGuire J.A., Stein-Oakley A.N., Dowling J., Smith R.E., Andrews R.K. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J. Clin. Endocrinol. Metab. 1995, 80:2203-2209.
24. Odermatt A., Arnold P., Frey F.J. The intracellular localization of the mineralocorticoid receptor is regulated by 11β-hydroxysteroid dehydrogenase type 2. J. Biol. Chem. 2001, 276:28484-28492.
25. Naray-Fejes-Toth A., Fejes-Toth G. Extranuclear localization of endogenous 11β-hydroxysteroid dehydrogenase-2 in aldosterone target cells. Endocrinology 1998, 139:2955-2959.
26. Whitworth J.A., Stewart P.M., Burt D., Atherden S.M., Edwards C.R. The kidney is the major site of cortisone production in man. Clin. Endocrinol. (Oxf.) 1989, 31:355-361.
27. Mercer W.R., Krozowski Z.S. Localization of an 11β-hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology 1992, 130:540-543.
28. Palermo M., Gomez-Sanchez C., Roitman E., Shackleton C.H. Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standards. Steroids 1996, 61:583-589.
29. Palermo M., Shackleton C.H., Mantero F., Stewart P.M. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin. Endocrinol. 1996, 45:605-611.
30. Shackleton C.H. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J. Steroid Biochem. Mol. Biol. 1993, 45:127-140.
31. Ferrari P., Sansonnens A., Dick B., Frey F.J. In vivo 11βHSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 2001, 38:1330-1336.
32. Corvol P., Michel J.B., Evin G., Gardes J., Bensala-Alaoui A., Menard J. The role of the renin-angiotensin system in blood pressure regulation in normotensive animals and man. J. Hypertens. Suppl. 1984, 2:S25-S30.
33. Funder J.W., Blair-West J.R., Coghlan J.P., Denton D.A., Scoggins B.S., Wright R.D. Effect of (K+) on the secretion of aldosterone. Endocrinology 1969, 85:381-384.
34. Griffith R.W. Freshwater or marine origin of the vertebrates?. Comp. Biochem. Physiol. A 1987, 87:523-531.
35. Cirillo M., Capasso G., Di Leo V.A., De Santo N.G. A history of salt. Am. J. Nephrol. 1994, 14:426-431.
36. Smith H.W. Renal Physiology 1964, Oxford University Press, New York.
37. Frassetto L., Morris R.C., Sellmeyer D.E., Todd K., Sebastian A. Diet, evolution and aging-the pathophysiologic effects of the post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in the human diet. Eur. J. Nutr. 2001, 40:200-213.
38. Kriz W. Structural organization of the renal medulla: comparative and functional aspects. Am. J. Physiol. 1981, 241:R3-R16.
39. Hu X., Funder J.W. The evolution of mineralocorticoid receptors. Mol. Endocrinol. 2006, 20:1471-1478.
40. Rocha R., Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci. 2002, 970:89-100.
41. Ferrari P., Bonny O. Forms of mineralocorticoid hypertension. Vitam. Horm. 2003, 66:113-156.
42. Tauchmanova L., Rossi R., Biondi B., Pulcrano M., Nuzzo V., Palmieri E.A., Fazio S., Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin. Endocrinol. Metab. 2002, 87:4872-4878.
43. Nasjletti A., Masson G.M. Effects of corticosteroids on plasma angiotensinogen and renin activity. Am. J. Physiol. 1969, 217:1396-1400.
44. Klett C., Hellmann W., Suzuki F., Nakanishi S., Ohkubo H., Ganten D., Hackenthal E. Induction of angiotensinogen mRNA in hepatocytes by angiotensin II and glucocorticoids. Clin. Exp. Hypertens. A 1988, 10:1009-1022.
45. Pirpiris M., Sudhir K., Yeung S., Jennings G., Whitworth J.A. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992, 19:567-574.
46. Ferrari P., Obeyesekere V.R., Li K., Andrews R.K., Krozowski Z.S. The 11β-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation. Steroids 1996, 61:197-200.
47. Stewart P.M., Walker B.R., Holder G., O'Halloran D., Shackleton C.H. 11β-hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 1995, 80:3617-3620.
48. Palermo M., Cossu M., Shackleton C.H. Cure of apparent mineralocorticoid excess by kidney transplantation. N. Engl. J. Med. 1998, 339:1787-1788.
49. Montrella-Waybill M., Clore J.N., Schoolwerth A.C., Watlington C.O. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J. Clin. Endocrinol. Metab. 1991, 72:1060-1066.
50. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J. Hypertens. Suppl. 1996, 14:S37-S41.
51. Fanestil D.D. Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochem. Pharmacol. 1968, 17:2240-2242.
52. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
53. Molnar G.A., Lindschau C., Dubrovska G., Mertens P.R., Kirsch T., Quinkler M., Gollasch M., Wresche S., Luft F.C., Muller D.N., Fiebeler A. Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 2008, 51:1372-1378.
54. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am. J. Physiol. 1992, 263:E1125-E1130.
55. Funder J.W. Mineralocorticoid receptors in the central nervous system. J. Steroid Biochem. Mol. Biol. 1996, 56:179-183.
56. Gomez-Sanchez E.P., Venkataraman M.T., Thwaites D., Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 1990, 258:E649-E653.
57. Mantero F., Opocher G., Rocco S., Carpene G., Armanini D. Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995, 60:81-86.
58. Ferrari P., Krozowski Z. Role of the 11β-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int. 2000, 57:1374-1381.
59. Ferrari P., Bianchetti M., Frey F.J. Juvenile hypertension, the role of genetically altered steroid metabolism. Horm. Res. 2001, 55:213-223.
60. Funder J., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264-5268.
61. Wilson R.C., Krozowski Z.S., Li K., Obeyesekere V.R., Razzaghy-Azar M., Harbison M.D., Wei J.Q., Shackleton C.H., Funder J.W., New M.I. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1995, 80:2263-2266.
62. Obeyesekere V.R., Ferrari P., Andrews R.K., Wilson R.C., New M.I., Funder J.W., Krozowski Z.S. The R337C mutation generates a high Km 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1995, 80:3381-3383.
63. Mune T., Rogerson F.M., Nikkila H., Agarwal A.K., White P.C. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet. 1995, 10:394-399.
64. Ferrari P., Obeyesekere V.R., Li K., Wilson R.C., New M.I., Funder J.W., Krozowski Z.S. Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol. Cell Endocrinol. 1996, 119:21-24.
65. Stewart P.M., Krozowski Z.S., Gupta A., Milford D.V., Howie A.J., Sheppard M.C., Whorwood C.B. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996, 347:88-91.
66. Kitanaka S., Katsumata N., Tanae A., Hibi I., Takeyama K., Fuse H., Kato S., Tanaka T. A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1997, 82:4054-4058.
67. Krozowski Z.S., Stewart P.M., Obeyesekere V.R., Li K., Ferrari P. Mutations in the 11β-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth. Clin. Exp. Hypertens. 1997, 19:519-529.
68. Li A., Li K.X., Marui S., Krozowski Z.S., Batista M.C., Whorwood C.B., Arnhold I.J., Shackleton C.H., Mendonca B.B., Stewart P.M. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J. Hypertens. 1997, 15:1397-1402.
69. Rogoff D., Smolenicka Z., Bergada I., Vallejo G., Barontini M., Heinrich J.J., Ferrari P. The codon 213 of the 11β-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1998, 83:4391-4393.
70. Wilson R.C., Dave-Sharma S., Wei J.Q., Obeyesekere V.R., Li K., Ferrari P., Krozowski Z.S., Shackleton C.H., Bradlow L., Wiens T., New M.I. A genetic defect resulting in mild low-renin hypertension. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10200-10205.
71. Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R., Krozowski Z.S., Funder J.W., Shackleton C.H., Bradlow H.L., Wei J.Q., Hertecant J., Moran A., Neiberger R.E., Balfe J.W., Fattah A., Daneman D., Akkurt H.I., De Santis C., New M.I. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 1998, 83:2244-2254.
72. Li A., Tedde R., Krozowski Z.S., Pala A., Li K.X., Shackleton C.H., Mantero F., Palermo M., Stewart P.M. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am. J. Hum. Genet. 1998, 63:370-379.
73. Odermatt A., Dick B., Arnold P., Zaehner T., Plueschke V., Deregibus M.N., Repetto H., Frey B.M., Frey F.J., Ferrari P. A mutation in the cofactor-binding domain of 11β-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J. Clin. Endocrinol. Metab. 2001, 86:1247-1252.
74. Carvajal C.A., Gonzalez A.A., Romero D.G., Gonzalez A., Mosso L.M., Lagos E.T., Hevia Mdel P., Rosati M.P., Perez-Acle T.O., Gomez-Sanchez C.E., Montero J.A., Fardella C.E. Two homozygous mutations in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 2003, 88:2501-2507.
75. Lavery G.G., Ronconi V., Draper N., Rabbitt E.H., Lyons V., Chapman K.E., Walker E.A., McTernan C.L., Giacchetti G., Mantero F., Seckl J.R., Edwards C.R., Connell J.M., Hewison M., Stewart P.M. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003, 42:123-129.
76. Quinkler M., Bappal B., Draper N., Atterbury A.J., Lavery G.G., Walker E.A., DeSilva V., Taylor N.F., Hala S., Rajendra N., Stewart P.M. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol. Cell Endocrinol. 2004, 217:143-149.
77. Lin-Su K., Zhou P., Arora N., Betensky B.P., New M.I., Wilson R.C. In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 2004, 89:2024-2027.
78. Mantero F., Tedde R., Opocher G., Dessi Fulgheri P., Arnaldi G., Ulick S. Apparent mineralocorticoid excess type II. Steroids 1994, 59:80-83.
79. Litchfield W.R., Hunt S.C., Jeunemaitre X., Fisher N.D., Hopkins P.N., Williams R.R., Corvol P., Williams G.H. Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. Hypertension 1998, 31:569-574.
80. Fiore C., Eisenhut M., Ragazzi E., Zanchin G., Armanini D. A history of the therapeutic use of liquorice in Europe. J. Ethnopharmacol. 2005, 99:317-324.
81. Henman F.D. Inhibition of peptic activity by carbenoxolone and glycyrrhetinic acid. Gut 1970, 11:344-351.
82. Stewart P.M., Whorwood C.B., Walker B.R. Steroid hormones and hypertension: the cortisol-cortisone shuttle. Steroids 1993, 58:614-620.
83. MacKenzie M.A., Hoefnagels W.H., Jansen R.W., Benraad T.J., Kloppenborg P.W. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J. Clin. Endocrinol. Metab. 1990, 70:1637-1643.
84. Whorwood C.B., Sheppard M.C., Stewart P.M. Licorice inhibits 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993, 132:2287-2292.
85. Morris D.J. Liquorice: new insights into mineralocorticoid and glucocorticoid hypertension. R I Med. 1993, 76:251-254.
86. Bernardi M., D'Intino P.E., Trevisani F., Cantelli-Forti G., Raggi M.A., Turchetto E., Gasbarrini G. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci. 1994, 55:863-872.
87. Stewart P.M., Murry B.A., Mason J.I. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J. Clin. Endocrinol. Metab. 1994, 79:480-484.
88. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H., Edwards C.R. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2:821-824.
89. Gitelman H.J., Graham J.B., Welt L.G. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans. Assoc. Am. Physicians 1966, 79:221-235.
90. Simon D.B., Karet F.E., Hamdan J.M., DiPietro A., Sanjad S.A., Lifton R.P. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 1996, 13:183-188.
91. Iwata F., Takashima H. Gitelman syndrome and hypocalciuria. J. Pediatr. 1992, 121:666-667.
92. Beretta-Piccoli C., Davies D.L., Boddy K., Brown J.J., Cumming A.M., East B.W., Fraser R., Lever A.F., Padfield P.L., Semple P.F., Robertson J.I., Weidmann P., Williams E.D. Relation of arterial pressure with body sodium, body potassium and plasma potassium in essential hypertension. Clin. Sci. 1982, 63:257-270.
93. Walker B.R., Stewart P.M., Shackleton C.H., Padfield P.L., Edwards C.R. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin. Endocrinol. 1993, 39:221-227.
94. Soro A., Ingram M.C., Tonolo G., Glorioso N., Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 1995, 25:67-70.
95. Walker B.R., Phillips D.I., Noon J.P., Panarelli M., Andrew R., Edwards H.V., Holton D.W., Seckl J.R., Webb D.J., Watt G.C. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998, 31:891-895.
96. Henschkowski J., Stuck A.E., Frey B.M., Gillmann G., Dick B., Frey F.J., Mohaupt M.G. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am. J. Hypertens. 2008, 21:644-649.
97. Inada M., Iwasaki K., Imai C., Hashimoto S. Spironolactone effective hypertension in the elderly due to 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) impairment: contributory role of determining serum cortisol/cortisone ratio as a marker of 11beta-HSD2 activity. Intern. Med. 2008, 47:2157-2164.
98. Olivieri O., Pizzolo F., Ravagnani V., Moretti L., Carletto A., Faccini G., Pasini F., Friso S., Corrocher R. Urinary cortisol to cortisone metabolites ratio in prednisone-treated and spontaneously hypertensive patients. J. Hypertens. 2008, 26:486-493.
99. Iki K., Miyamori I., Hatakeyama H., Yoneda T., Takeda Y., Takeda R., Dai Q.L. The activities of 5β-reductase and 11β-hydroxysteroid dehydrogenase in essential hypertension. Steroids 1994, 59:656-660.
100. Santini D.L., Lorenzo B.J., Koufis T., Reidenberg M.M. Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics. Am. J. Hypertens. 1995, 8:516-519.
101. Sullivan J.M. Salt sensitivity. Definition, conception, methodology, and long-term issues. Hypertension 1991, 17:I61-I68.
102. Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension 1996, 27:481-490.
103. Sharma A.M. Salt sensitivity as a phenotype for genetic studies of human hypertension. Nephrol. Dial Transplant. 1996, 11:927-929.
104. Lovati E., Ferrari P., Dick B., Jostarndt K., Frey B.M., Frey F.J., Schorr U., Sharma A.M. Molecular basis of human salt-sensitivity: the role of the 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Endocrinol. Metab. 1999, 84:3745-3749.
105. Burton P.J., Waddell B.J. 11β-hydroxysteroid dehydrogenase in the rat placenta: developmental changes and the effects of altered glucocorticoid exposure. J. Endocrinol. 1994, 143:505-513.
106. Barker D.J., Osmond C., Golding J., Kuh D., Wadsworth M.E. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Bmj 1989, 298:564-567.
107. Lindsay R.S., Lindsay R.M., Waddell B.J., Seckl J.R. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996, 39:1299-1305.
108. Edwards C.R., Benediktsson R., Lindsay R.S., Seckl J.R. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension?. Lancet 1993, 341:355-357.
109. Seckl J.R., Benediktsson R., Lindsay R.S., Brown R.W. Placental 11β-hydroxysteroid dehydrogenase and the programming of hypertension. J. Steroid Biochem. Mol. Biol. 1995, 55:447-455.
110. Watson B., Bergman S.M., Myracle A., Callen D.F., Acton R.T., Warnock D.G. Genetic association of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996, 28:478-482.
111. Smolenicka Z., Bach E., Schaer A., Liechti-Gallati S., Frey B.M., Frey F.J., Ferrari P. A new polymorphic restriction site in the human 11β-hydroxysteroid dehydrogenase type 2 gene. J. Clin. Endocrinol. Metab. 1998, 83:1814-1817.
112. Zaehner T., Plueshke V., Frey B.M., Frey F.J., Ferrari P. Structural analysis of the 11β-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. Kidney Int. 2000, 58:1413-1419.
113. Kamide K., Kokubo Y., Hanada H., Nagura J., Yang J., Takiuchi S., Tanaka C., Banno M., Miwa Y., Yoshii M., Matayoshi T., Yasuda H., Horio T., Okayama A., Tomoike H., Kawano Y., Miyata T. Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens. Res. 2006, 29:243-252.
114. Brand E., Kato N., Chatelain N., Krozowski Z.S., Jeunemaitre X., Corvol P., Plouin P.F., Cambien F., Pascoe L., Soubrier F. Structural analysis and evaluation of the 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) gene in human essential hypertension. J. Hypertens. 1998, 16:1627-1633.
115. Agarwal A.K., Giacchetti G., Lavery G., Nikkila H., Palermo M., Ricketts M., McTernan C., Bianchi G., Manunta P., Strazzullo P., Mantero F., White P.C., Stewart P.M. CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 2000, 36:187-194.
116. Weber C.S., Thayer J.F., Rudat M., Sharma A.M., Perschel F.H., Buchholz K., Deter H.C. Salt-sensitive men show reduced heart rate variability, lower norepinephrine and enhanced cortisol during mental stress. J. Hum. Hypertens. 2008, 22:423-431.
117. Mariniello B., Ronconi V., Sardu C., Pagliericcio A., Galletti F., Strazzullo P., Palermo M., Boscaro M., Stewart P.M., Mantero F., Giacchetti G. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am. J. Hypertens. 2005, 18:1091-1098.
118. Agalou S., Butt A.N., Chowienczyk P., Swaminathan R. Hypertension and circulating mRNA for 11beta-hydroxysteroid dehydrogenase type II. Ann. N. Y. Acad. Sci. 2008, 1137:290-295.
119. Friso S., Pizzolo F., Choi S.W., Guarini P., Castagna A., Ravagnani V., Carletto A., Pattini P., Corrocher R., Olivieri O. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 2008, 199:323-327.